MedTrace Logo

Cellular-Mediated Immunity in COVID-19

NCT04746521 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-02-14

No results posted yet for this study

Summary

In order to prevent reinfection, it is needed to detect the cellular-mediated immune response to the Sars-CoV-2 infection. The first goal of this study will be to detect the cellular-mediated immune response in patients affected by COVID-19 (with or without vaccination) and healthy subjects who undergone vaccination program. The second goal of this study will be to identify the genetic and epigenetic biomarkers that influence individual immunological response and clinical evolution to the severe manifestations of the COVID-19.

Conditions

  • Covid19
  • Thromboembolism

Interventions

DIAGNOSTIC_TEST

Multitest 6 color TBNK and BD Lyotubes

The Multitest 6 color TBNK allows us to count the population-specific B, T, NK cells

BIOLOGICAL

genomicDNA extraction

Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood \& Tissue kit (QIAGEN), according to manufacturer protocols

Sponsors & Collaborators

  • University of Campania Luigi Vanvitelli

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-14
Primary Completion
2022-01-14
Completion
2022-12-14

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746521 on ClinicalTrials.gov